OCT 30·SEC EDGARLow
Girao Tiago sold $188K of IMVT
Girao Tiago (Chief Financial Officer) sold 6,606 shares of Immunovant, Inc. (IMVT) at $28.50 ($0.19M total) on 2026-10-28.
StockNASDAQ · US · USDHealthcare · Biotechnology
$IMVT
Immunovant, Inc.
Immunovant is a clinical-stage immunology company developing treatments for people with autoimmune diseases. Its main product candidate, IMVT-1402, also called imeroprubart, is a fully human monoclonal antibody that inhibits FcRn, a target involved in regulating IgG antibodies. Immunovant is studying IMVT-1402 in six indications across endocrinology, rheumatology, dermatology and neurology, including Graves’ disease, difficult-to-treat rheumatoid arthritis, Sjögren’s disease, cutaneous lupus erythematosus, myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Its studies use a subcutaneous formulation and the YpsoMate autoinjector. Immunovant discontinued development of its earlier candidate, batoclimab, and is focusing on IMVT-1402. The company is headquartered in Durham, North Carolina.
Price · $IMVTvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $IMVT in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $500K 6 txs
Stout Jay S3× · $197K
10b5-1 share of filings0%
Top stories · $IMVTMore →
OCT 10·investing.com
Immunovant CTO Jay Stout sells $122,116 in shares
Immunovant CTO Jay Stout sold 3,809 shares worth $122,116 to cover tax obligations from RSU vesting. Shares trade at $30.47, down 9% weekly but up 79% yearly. IMVT-1402 failed a clinical trial, but H.C. Wainwright maintains a $41 target. Roivant Sciences reported a larger Q1 loss than expected.
OCT 9·SEC EDGAR
Stout Jay S sold $122K of IMVT
Stout Jay S (Chief Technology Officer) sold 3,809 shares of Immunovant, Inc. (IMVT) at $32.06 ($0.12M total) across 2 trades on 2026-10-07.
IMVT sentiment & insider activity
Recent IMVT coverage spans insider activity, financial news and technology.
In the last 30 days, IMVT insiders filed 6 SEC Form 4 transactions — no purchases and 6 sales ($500K). The most active reporter was Stout Jay S, Chief Technology Officer, with 3 filings.
What's driving IMVT
The insider sale may create modest selling pressure on IMVT.
The insider sale and negative trial result both suggest downside pressure on the stock.
The insider sale may signal reduced confidence or liquidity need, potentially pressuring the stock.
Clinical-trial failure risk for IMVT-1402 likely pressures sentiment and valuation for the Sjögren’s program read-through.
Immunovant dropped 4.8% in pre‑market after the trial miss was disclosed.
AlphAI scores every news story that mentions IMVT with an AI model for sentiment and relevance, and aggregates insider trades from Immunovant, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $IMVT
Score
Girao Tiago sold $188K of IMVT
Girao Tiago (Chief Financial Officer) sold 6,606 shares of Immunovant, Inc. (IMVT) at $28.50 ($0.19M total) on 2026-10-28.
1 min readImmunovant CTO Jay Stout sells $122,116 in shares
Immunovant CTO Jay Stout sold 3,809 shares worth $122,116 to cover tax obligations from RSU vesting. Shares trade at $30.47, down 9% weekly but up 79% yearly. IMVT-1402 failed a clinical trial, but H.C. Wainwright maintains a $41 target. Roivant Sciences reported a larger Q1 loss than expected.
2 min readStout Jay S sold $122K of IMVT
Stout Jay S (Chief Technology Officer) sold 3,809 shares of Immunovant, Inc. (IMVT) at $32.06 ($0.12M total) across 2 trades on 2026-10-07.
1 min readIMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Argenx's Sjögren’s trial failure caused Immunovant (IMVT) and Roivant (ROIV) stocks to slide, raising concerns about their similar studies. Wainwright maintained a 'Buy' rating on Argenx (ARGX) with a $1,202 price target. Retail sentiment shifted from bearish to bullish for ARGX, while IMVT and ROIV saw neutral and bearish sentiment, respectively. Year-to-date, IMVT is up 19%, ROIV up 55%, and ARGX down 4%.
3 min readArgenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session - argenx (
Argenx (ARGX) shares fell 8.7% in pre-market trading after discontinuing a Phase 3 study for futility. Other stocks moving lower include Caribou Biosciences (CRBU), down 3.7% after a downgrade, and several others with declines ranging from 1.8% to 7.4%.
2 min readVenker Eric sold $120K of IMVT
Venker Eric (Chief Executive Officer) sold 3,506 shares of Immunovant, Inc. (IMVT) at $34.11 ($0.12M total) on 2026-10-02.
1 min readVenker Eric sold (to issuer) $2.9M of IMVT
Venker Eric (Chief Executive Officer) sold (to issuer) 85,886 shares of Immunovant, Inc. (IMVT) at $33.65 ($2.89M total) on 2026-10-01.
1 min read
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
Immunovant (IMVT) reported a Phase 2b trial failure for IMVT-1402 in CLE, discontinuing development. Despite missing the primary endpoint, the drug showed positive trends and a favorable safety profile. IMVT-1402 is still being tested in five other autoimmune diseases, with data expected from 2027. The company has $797.8M in cash, and hedge fund interest has increased.
2 min readVan Tuyl Christopher sold $103K of IMVT
Van Tuyl Christopher (Chief Legal Officer) sold 2,846 shares of Immunovant, Inc. (IMVT) at $36.36 ($0.10M total) on 2026-09-23.
1 min readRoivant slips on trial setback for Immunovant (ROIV:NASDAQ)
Roivant (ROIV) fell premarket after its subsidiary Immunovant (IMVT) reported a failed trial for IMVT-1402, a treatment for cutaneous lupus erythematosus, based on 12-week data.
1 min read